Ibandronate: The loading dose concept in the treatment of metastatic bone pain
Open Access
- 1 March 2016
- journal article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 5 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trialThe Lancet Oncology, 2014
- Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe PainOnkologie, 2012
- Long-Term Renal Safety Profile of Ibandronate 6 mg Infused over 15 MinutesOnkologie, 2010
- Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone CancerJournal of Pain and Symptom Management, 2008
- Bisphosphonates for breast cancer2005
- Optimization of opioid therapy for preventing incident pain associated with bone metastasesJournal of Pain and Symptom Management, 2004
- Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerPain, 2004
- Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnnals of Oncology, 2003
- Bisphosphonates for cancer patients: why, how, and when?Supportive Care in Cancer, 2001
- [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].2001